| Size | Price | |
|---|---|---|
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
There is a type of hereditary disease called porphyria, which is characterized by an error in the heme synthesis metabolic pathway. |
|---|---|
| Toxicity/Toxicokinetics |
Protein Binding
This means that, compared to adult hemoglobin, the oxygen binding curve of fetal hemoglobin is shifted to the left (i.e., a higher proportion of hemoglobin binds to oxygen at lower oxygen tension). |
| References | |
| Additional Infomation |
The respiratory protein of red blood cells. It is mainly composed of globin and heme.
See also: Hemoglobin (note moved to). Drug Indications Studied for the treatment of blood disorders (diseases of hematopoietic organs, not specified) and bleeding. Mechanism of Action The heme group consists of an iron (Fe) ion (charged atom) located in a heterocyclic ring (also called a porphyrin ring). The iron ion at the oxygen binding site binds to the nitrogen atom located at the center of the porphyrin ring. The iron ion binds with high affinity to the globular protein through the imidazole ring of histidine residue F8 located below the porphyrin ring. The sixth position reversibly binds to oxygen, thus completing the formation of the octahedral group. One oxygen atom binds to iron, and another oxygen atom protrudes at a certain angle. When the oxygen atom is not bound to the iron atom, water molecules (weakly bound) fill the position, forming a twisted shape, usually described as an octahedron. |
| Molecular Weight |
0
|
|---|---|
| Exact Mass |
226.074
|
| CAS # |
9008-02-0
|
| PubChem CID |
13285535
|
| Appearance |
Brown to reddish brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
400.9±45.0 °C at 760 mmHg
|
| Flash Point |
196.3±28.7 °C
|
| Vapour Pressure |
0.0±0.9 mmHg at 25°C
|
| Index of Refraction |
1.609
|
| LogP |
2.95
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
17
|
| Complexity |
353
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
INGWEZCOABYORO-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C13H10N2O2/c1-8-4-5-9-11(16)7-10(15-13(9)14-8)12-3-2-6-17-12/h2-7H,1H3,(H,14,15,16)
|
| Chemical Name |
2-(furan-2-yl)-7-methyl-1H-1,8-naphthyridin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
An evaluation of pressure ulcer using fingerstall-type tissue oximetry
CTID: UMIN000032921
PhaseNot applicable Status: Complete: follow-up complete
Date: 2018-07-01
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
